Is Immunocore Holdings plc (IMCR) A Good Stock To Buy?
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (
Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. In this article, we will take a closer look at hedge fund sentiment towards Immunocore Holdings plc (NASDAQ:IMCR).
Is IMCR a good stock to buy? Hedge funds were becoming hopeful. The number of long hedge fund positions inched up by 17 recently. Immunocore Holdings plc (NASDAQ:IMCR) was in 17 hedge funds’ portfolios at the end of the first quarter of 2021. Our calculations also showed that IMCR isn’t among the 30 most popular stocks among hedge funds (click for Q1 rankings).
Harmony Biosciences Announces Date Of Second Quarter 2021 Financial Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Harmony Biosciences Presents New Analysis Of Clinical Impact For WAKIX® (pitolisant) At The SLEEP 2021 Annual Meeting
Data highlight the clinical effectiveness of WAKIX for excessive daytime sleepiness and cataplexy in adults with narcolepsy
News provided by
Share this article
Share this article
PLYMOUTH MEETING, Pa., June 10, 2021 /PRNewswire/ Harmony Biosciences Holdings, Inc. ( Harmony ) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced results of a new analysis evaluating number needed to treat (NNT) and effect sizes for treatment with WAKIX
® (pitolisant) that demonstrates the magnitude of its clinical effectiveness for excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The poster was presented at the 35